For the first quarter of 2010, the company posted net earnings of $169m, compared to $45m for the prior year period. Operating income was $250.3m, compared to $82.1 for the year ago period.
For the second quarter of 2010, the company expects total product net sales between $1,190m and $1,230m. Non-GAAP diluted earnings per share attributable to stockholders between $0.79 and $0.81, which includes the estimated impact of US healthcare reform legislation.
David Pyott, chairman of the board and CEO of Allergan, said: “During the first quarter, Allergan continued to actively expand its product portfolio and geographic reach through business development activities and the attainment of important regulatory approvals. In addition, we delivered strong operating results as we benefited from the increasing strength of our cash pay businesses.”
Will the company reach expected product sales in Q2?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.